Dr. Priscilla Anne Furth, MD
- Infectious Diseases
Priscilla A. Furth, MD, is a specialist in Internal Medicine with a subspecialty in infectious disease. Dr. Furth is professor of Oncology and Medicine and associate dean for Faculty Development at Georgetown University. In the clinic, she concentrates on cancer survivorship, focusing on fitness and metabolism, and also maintains an NIH-funded basic science research laboratory examining molecular issues in cancer pathophysiology.
Dr. Furth's Philosophy of Care
I strive to provide patients with expert guidance and information to improve their health. My practice focus is cancer survivorship and empowering patients through physical exercise and nutrition for improved well-being. We know that holistic approaches to cancer recovery have the best outcomes. These approaches address a person's lifestyle needs and their medical needs. I help individuals recovering from cancer remain physically healthy by helping them understand their nutritional and exercise needs and by teaching them how to create a healthful lifestyle for themselves following treatment.
- Fellowship Program: National Institutes of Health Clinical Center (1992)
- Fellowship Program: Harvard Medical School (1985)
- Residency Program: Mount Sinai Medical Center (1982)
- Internship Program: Mount Sinai Medical Center (1980)
- Medical School: Yale University School of Medicine (1979)
- Board Certification: American Board of Internal Medicine, Infectious Disease
- Board Certification: American Board of Internal Medicine, Internal Medicine
- Application of Primary Culture of Salivary Gland Benign and Malignant Tumors under Conditional Reprogramming Conditions for Definition of Tumor-Associated Genetic Changes. American Head and Neck Society annual meeting and translational research meeting. Selected for oral presentation. 2015.
- Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance. Carcinogenesis. 2015.
- The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers. Mol Carcinog.
- Human pancreatic cancer-associated stellate cells remain activated after in vivo Frontiers in Oncology. 2014
- MedStar Georgetown University Hospital
- Georgetown Women in Medicine Outstanding Achievement Award
- Noel Soderberg Evans Award in Breast Cancer Research, Washington, DC